Cargando…
Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells
BACKGROUND: Cholangiocarcinoma (CCA) is a fatal cancer with high resistance to anticancer drugs. The development of new drugs or compounds to be used alone or in combination with currently available chemotherapeutic agents to improve the treatment of CCA is needed. Compound A (CpdA), which is a smal...
Autores principales: | Junking, Mutita, Rattanaburee, Thidarath, Panya, Aussara, Budunova, Irina, Haegeman, Guy, Yenchitsomanus, Pa-Thai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779449/ https://www.ncbi.nlm.nih.gov/pubmed/32986368 http://dx.doi.org/10.31557/APJCP.2020.21.9.2673 |
Ejemplares similares
-
Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells
por: Chiawpanit, Chutipa, et al.
Publicado: (2022) -
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
por: Supimon, Kamonlapat, et al.
Publicado: (2021) -
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
por: Wutti-in, Yupanun, et al.
Publicado: (2022) -
Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
por: Sangsuwannukul, Thanich, et al.
Publicado: (2022) -
Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)